Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer
Foresee Pharmaceuticals announced the appointment of Brian J. Groch as Chief Commercial Officer, effective July 1, 2026. Groch will lead global commercial launch strategy and preparations for FP-001 42 mg for central precocious puberty.
Taipei – Foresee Pharmaceuticals announced on July 9, 2026, that Brian J. Groch has been appointed Chief Commercial Officer, effective July 1, 2026. In this role, Groch will oversee the global commercial launch strategy and preparations for FP-001 42 mg, a ready-to-use six-month long-acting injectable formulation of leuprolide mesylate for the treatment of central precocious puberty (CPP).
Groch brings over 30 years of experience in the pharmaceutical industry, having held leadership positions at companies including Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. His background includes extensive experience in leading global market access strategies and commercial execution.
"Brian will lead Foresee in building a commercial team to launch FP-001 for the treatment of CPP patients in the U.S., Taiwan, and potentially other selected countries," said Dr. Ben Chien, Chairman and CEO of Foresee Pharmaceuticals. The company is targeting a New Drug Application submission to the U.S. Food and Drug Administration (FDA) in the second half of 2026. Marketing authorization applications will also be submitted to health agencies in Taiwan and other strategic territories between late 2026 and the first half of 2027.
Central precocious puberty is a condition characterized by premature activation of the pituitary-gonadal axis. If left untreated, it can result in accelerated bone maturation and reduced final adult height, as well as psychosocial challenges. FP-001 42 mg is an investigational, sustained-release formulation designed to provide six months of continuous suppression of gonadotropin secretion following a single injection.